e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Healthcare and treatment of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The study of influence of different bronchodilatators in the patients with exacerbation of chronic obstructive disease (COPD) and benign prostatic hyperplasia (bph)
N. Berdnikova, D. Tsiganko, M. Averyianov (Moscow, Russian Federation)
Source:
Annual Congress 2009 - Healthcare and treatment of COPD
Session:
Healthcare and treatment of COPD
Session type:
Thematic Poster Session
Number:
3455
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Berdnikova, D. Tsiganko, M. Averyianov (Moscow, Russian Federation). The study of influence of different bronchodilatators in the patients with exacerbation of chronic obstructive disease (COPD) and benign prostatic hyperplasia (bph). Eur Respir J 2009; 34: Suppl. 53, 3455
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The state of patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007
Can chronic obstructive lung disease (COPD) criteria be used to manage bronchiectasis (BR) and obliterative bronchiolitis (OB) in children surviving severe lung infection?
Source: Eur Respir J 2001; 18: Suppl. 33, 172s
Year: 2001
Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity
Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)?
Year: 2018
Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)?
Source: Eur Respir J 2001; 18: Suppl. 33, 241s
Year: 2001
Next generation sequencing in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD)
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008
Longitudinal study of FEO1 as a criterion for bronchial obstruction in outpatients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 64s
Year: 2005
The metabolic syndrome (MetS) in patients with chronic obstructive pulmonary disease (COPD) and its association with airway obstruction
Source: Annual Congress 2012 - COPD is not a pulmonary disease alone
Year: 2012
Bronchiectasis impact outcomes in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
The relationship between fibroblasts and airway structure in patients with asthma and chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 148s
Year: 2001
The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease)
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 241s
Year: 2003
Microbiological features of the indicators of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) during remission
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Chronic obstructive pulmonary disease (COPD) patients with bronchiectasis: clinical features?
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Is the severity of oxidative stress different in patients with end stage chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation?
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007
Subpopulation structure of lymphocytes in patients with chronic obstructive pulmonary disease (COPD) during exacerbation and after treatment
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
The characteristic of chronic renal dysfunction in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Predictive factors for the incidence of lung cancer (LC) complicated in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2019 – Advances in clinical management of COPD
Year: 2019
Functional and inflammatory bowel diseases in patients with chronic obstructive pulmonary disease (COPD).
Source: International Congress 2019 – Advances in clinical management of COPD
Year: 2019
Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients
Source: Annual Congress 2006 - COPD therapy
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept